BioCentury | Jan 15, 2015
Finance

Consortia cross-talk

There's no doubt that the consortium model is here to stay, but the challenge now is to avoid creating a bureaucracy of committees with duplicate missions and redundancies of effort. The answer might be a...
BioCentury | Aug 15, 2013
Translation in Brief

Translational tidbits

Scripps' Sigma factor Academic and industry researchers eager to use new tool compounds typically must reproduce synthetic schemes published in academic journals or wait months for reagent makers to list new compounds in their catalogs....
BioCentury | Jul 29, 2013
Company News

AB Science, Skuldtech, Brain and Spine Institute (ICM), French Alternative Energies and Atomic Energy Commission (CEA), French National Institute of Health and

The partners formed the ROMANE consortium, which will receive €8.6 million ($11.3 million) from the Strategic Industrial Innovation (ISI) program of Bpifrance (formerly OSEO), the French innovation funding agency, to develop AB Science's masitinib to...
BioCentury | Jul 15, 2013
Company News

BioAlliance, DBI S.A.S., Nanobiotix, Institute Galien Paris-Sud, CEA-Leti cancer news

BioAlliance announced that it is leading the newly formed Nano Innovation for Cancer (NICE) five-member consortium, which received about €9 million ($11.7 million) in funding through the Strategic Industrial Innovation (ISI) program of bpifrance (formerly...
BioCentury | Jun 3, 2013
Financial News

Theravectys completes venture financing

Theravectys S.A. , Paris, France Business: Infectious Date completed: 5/29/13 Type: Venture financing Raised: €1.2 million ($1.6 million) Investor: OSEO Note: Theravectys received the interest-free loan under OSEO's Development of Innovation assistance program. WIR Staff Infectious...
BioCentury | Apr 15, 2013
Company News

Splicos S.A.S., Theradiag, French National Center for Research and Science diagnostic, pharmacogenetics news

Diagnostics company Theradiag will receive €1.2 million ($1.6 million) from OSEO, the French innovation funding agency, to develop four test kits under the CaReNA project. In 2011, the companies and institution formed the CaReNA project...
BioCentury | Mar 18, 2013
Company News

Ariana, CTI Biotech, Ipsen, Pierre Fabre, Oncodesign, Oncomedics, Transgene, Merieux NutriSciences Corp., Sanofi, Servier cancer news

The IMODI project has an expected budget of €41 million ($53.3 million), including €27.6 million ($35.9 million) in private investment. The pharmas include Sanofi, Servier, Ipsen, Pierre Fabre, Transgene and the Biofortis subsidiary of Merieux...
BioCentury | Mar 13, 2013
Politics & Policy

Public-private partnership receives EUR 13.4M for cancer project

OSEO, the French innovation funding agency, awarded EUR 13.4 million ($17.4 million) to a public-private partnership aiming to build a national network to develop predictive experimental cancer models. Oncodesign S.A. (Dijon, France) will lead the...
BioCentury | Feb 4, 2013
Company News

Provence Technologies S.A.S. pharmaceuticals news

R&D services company Provence launched Screening 1000, a $1.7 million research program to discover and develop an "ultra-pure molecule for the healthcare market." France's OSEO agency and Provence Technologies are co-funding the two-year project equally....
BioCentury | Nov 19, 2012
Company News

DBV, Genclis S.A.S., Hospices Civils de Lyon inflammation, diagnostic news

DBV announced it will use its Viaskin technology to develop Viaskin HDM to treat house dust mite allergy in children. The program will be conducted under ImmunAVia, a joint project with diagnostic company Genclis and...
Items per page:
1 - 10 of 29
BioCentury | Jan 15, 2015
Finance

Consortia cross-talk

There's no doubt that the consortium model is here to stay, but the challenge now is to avoid creating a bureaucracy of committees with duplicate missions and redundancies of effort. The answer might be a...
BioCentury | Aug 15, 2013
Translation in Brief

Translational tidbits

Scripps' Sigma factor Academic and industry researchers eager to use new tool compounds typically must reproduce synthetic schemes published in academic journals or wait months for reagent makers to list new compounds in their catalogs....
BioCentury | Jul 29, 2013
Company News

AB Science, Skuldtech, Brain and Spine Institute (ICM), French Alternative Energies and Atomic Energy Commission (CEA), French National Institute of Health and

The partners formed the ROMANE consortium, which will receive €8.6 million ($11.3 million) from the Strategic Industrial Innovation (ISI) program of Bpifrance (formerly OSEO), the French innovation funding agency, to develop AB Science's masitinib to...
BioCentury | Jul 15, 2013
Company News

BioAlliance, DBI S.A.S., Nanobiotix, Institute Galien Paris-Sud, CEA-Leti cancer news

BioAlliance announced that it is leading the newly formed Nano Innovation for Cancer (NICE) five-member consortium, which received about €9 million ($11.7 million) in funding through the Strategic Industrial Innovation (ISI) program of bpifrance (formerly...
BioCentury | Jun 3, 2013
Financial News

Theravectys completes venture financing

Theravectys S.A. , Paris, France Business: Infectious Date completed: 5/29/13 Type: Venture financing Raised: €1.2 million ($1.6 million) Investor: OSEO Note: Theravectys received the interest-free loan under OSEO's Development of Innovation assistance program. WIR Staff Infectious...
BioCentury | Apr 15, 2013
Company News

Splicos S.A.S., Theradiag, French National Center for Research and Science diagnostic, pharmacogenetics news

Diagnostics company Theradiag will receive €1.2 million ($1.6 million) from OSEO, the French innovation funding agency, to develop four test kits under the CaReNA project. In 2011, the companies and institution formed the CaReNA project...
BioCentury | Mar 18, 2013
Company News

Ariana, CTI Biotech, Ipsen, Pierre Fabre, Oncodesign, Oncomedics, Transgene, Merieux NutriSciences Corp., Sanofi, Servier cancer news

The IMODI project has an expected budget of €41 million ($53.3 million), including €27.6 million ($35.9 million) in private investment. The pharmas include Sanofi, Servier, Ipsen, Pierre Fabre, Transgene and the Biofortis subsidiary of Merieux...
BioCentury | Mar 13, 2013
Politics & Policy

Public-private partnership receives EUR 13.4M for cancer project

OSEO, the French innovation funding agency, awarded EUR 13.4 million ($17.4 million) to a public-private partnership aiming to build a national network to develop predictive experimental cancer models. Oncodesign S.A. (Dijon, France) will lead the...
BioCentury | Feb 4, 2013
Company News

Provence Technologies S.A.S. pharmaceuticals news

R&D services company Provence launched Screening 1000, a $1.7 million research program to discover and develop an "ultra-pure molecule for the healthcare market." France's OSEO agency and Provence Technologies are co-funding the two-year project equally....
BioCentury | Nov 19, 2012
Company News

DBV, Genclis S.A.S., Hospices Civils de Lyon inflammation, diagnostic news

DBV announced it will use its Viaskin technology to develop Viaskin HDM to treat house dust mite allergy in children. The program will be conducted under ImmunAVia, a joint project with diagnostic company Genclis and...
Items per page:
1 - 10 of 29